MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Boceprevir

CAS No. : 394730-60-0

MCE 国际站：Boceprevir

产品活性：Boceprevir (EBP 520) 是一种口服有效的选择性的 HCV NS3 protease 抑制剂，酶实验中K_i 为 14 nM，在含细胞体系的复制实验中，EC₉₀ 为 350 nM。Boceprevir 抑制 SARS-CoV-2 3CL^pro 活性。

研究领域：Anti-infection  |  Metabolic Enzyme/Protease

作用靶点：HCV Protease  |  HCV  |  SARS-CoV

In Vitro: In the HCV NS3 protease continuous assay, Boceprevir (SCH 503034) has a potency of 14 nM (K_i) average over a large number of runs. In the 72-h bicistronic subgenomic cell-based replicon assay in HuH-7 cells, the EC₅₀ and EC₉₀ values are determined to be 0.20 µM and 0.35 µM, respectively. Boceprevir is also found to be a very weak inhibitor of HNE (K_i=26 µM) representing a selectivity of 2200.

In Vivo: Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. The pharmacokinetic profile of Boceprevir is evaluated in several animal species. Following oral administration, Boceprevir is moderately absorbed in rats (10 mg/kg), dogs (3 mg/kg), and monkeys (3 mg/kg). Absorption is relatively rapid in dogs but slower in mice (10 mg/kg), rats, and monkeys, as evidenced by mean absorption times (MAT) ranging from 0.5 to 1.4 h. The AUC is good in dogs and rats, moderate in mouse, and low in monkeys. The absolute oral bioavailability is modest in mouse, rats, and dogs (26-34%) but low in monkeys (4%). Boceprevir (100 mg/kg, orally) inhibit HCV NS3/4A protease activity in triple-transgenic mice.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Hepatitis C Virus Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Targeted Diversity Library  |  EMA-Approved Drug Library  |  Heterocyclic Compound Library  |  Withdrawn Drug Compound Library  |  Off-patent Drug Library  |  Highly Selective Inhibitors Library  |  Sofosbuvir impurity J  |  Alisporivir  |  Antimicrobial agent-10  |  GS-9256  |  SARS-CoV-2-IN-23  |  PSI-7409 tetrasodium  |  3CPLro-IN-1  |  Dasabuvir  |  FNC-TP  |  DDX3-IN-1  |  SP inhibitor 1  |  rel-Zotatifin  |  Monodes(N-carboxymethyl)valine Daclatasvir  |  Antioxidant agent-9  |  Regdanvimab  |  Silymarin  |  NHC-triphosphate tetraammonium  |  Sofosbuvir-d₆  |  Grazoprevir potassium salt  |  Atazanavir  |  Daclatasvir-d₁₆  |  FWM-4  |  Amantadine-d₆  |  Deferiprone  |  Ketotifen fumarate  |  Dehydrojuncusol  |  Daclatasvir dihydrochloride  |  SARS-CoV-2-IN-27  |  Ribavirin  |  MMT5-14

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。